Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies —  — New indications for use as an...

Related Keywords

Pacira Biosciences ,Pacira Biosciences Inc ,Drug Administration ,Nasdaq ,Dave Stack ,Numerical Rating Scale ,Safety Information ,Markets ,